Erkang Pharmaceutical: Notice on holding an online briefing on 2025 annual results

Securities code: 300267 Securities abbreviation: Erkang Pharmaceutical Announcement number: 2026-008

Hunan Erkang Pharmaceutical Co., Ltd.

Notice on holding the 2025 annual performance online briefing

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

Hunan Erkang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") disclosed the 2025 annual report and its summary on April 23, 2026. In order to facilitate investors to have a better and more in-depth understanding of the company's operations, the company will hold an online briefing on the 2025 annual results from 15:00-17:00 on May 8, 2026 (Friday).

This annual performance briefing will be held remotely via the Internet. Investors can log in to Panorama's "Investor Relations Interactive Platform" (https://ir.p5w.net) to participate in this annual performance briefing. Personnel attending this annual report briefing include: Mr. Shuai Fangwen, chairman of the company, Mr. Gu Jishun, secretary of the board of directors, Ms. Zhao Xun, director and financial director, and Mr. Tan Xue, representative of independent directors.

In order to fully respect investors and improve the pertinence of communication, the company's 2025 annual performance briefing will openly solicit questions from investors and listen extensively to investors' opinions and suggestions. Investors can visit https://ir.p5w.net/zj/, or scan the QR code below to enter the special question collection page. The company will answer questions of common concern to investors at this performance briefing.

Investors are welcome to actively participate.

(QR code on the special page of question collection)

Announcement is hereby made.

Board of Directors of Hunan Erkang Pharmaceutical Co., Ltd.

April 22, 2026